Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment
12 December 2023 - 2:31AM
Dow Jones News
By Sabela Ojea
Shares of Poseida Therapeutics on Monday climbed after the
company said it received positive early results from the phase 1
trial for a blood cancer treatment.
At 9:43 a.m. ET, shares were up 21% at $3.83. The stock has,
however, dropped 75% in the past 12 months.
The clinical-stage cell and gene therapy company said its early
P-BCMA-ALLO1 clinical results inspire it to further develop the
treatment for relapsed-refractory multiple myeloma in partnership
with Roche.
Last year, Poseida said it signed a strategic collaboration with
the biotechnology company Roche.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 11, 2023 10:16 ET (15:16 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Poseida Therapeutics (NASDAQ:PSTX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Poseida Therapeutics (NASDAQ:PSTX)
Historical Stock Chart
From Nov 2023 to Nov 2024
